# Wolverine (BPC-157 + TB-500 Research Blend): Research Overview — Core Fusion Peptides > A literature summary of the Wolverine research blend (BPC-157 + TB-500): constituent mechanisms, animal-model healing findings, regulatory status, and why no combination study exists. BPC-157 supplies an angiogenic signal, TB-500 supplies a cytoskeletal-migration signal — a theoretically complementary pairing with no controlled combination trial behind it. ## The short version The **Wolverine blend** is the most widely discussed two-peptide tissue-repair stack in research-peptide communities. It combines **BPC-157** — a synthetic fifteen-amino-acid peptide from gastric juice, studied for promoting new blood-vessel growth into injured tissue [4] — with **TB-500**, the synthetic seven-amino-acid fragment (Ac-LKKTETQ) of the natural protein thymosin beta-4, studied for its role in the actin-driven cell migration that carries repair cells into a wound [5][6]. The combination rationale is that the two mechanisms are complementary and non-overlapping: BPC-157 grows the blood supply, TB-500 mobilizes the cells. In plain terms, the pairing is widely described as "synergistic," but here is the honest part: no controlled study has ever tested the Wolverine combination against its parts, against placebo, or in humans [2]. A 2025 systematic review of BPC-157 in orthopedic sports medicine found 36 studies — 35 preclinical and only 1 human — and explicitly noted no clinical safety data and no mention of any combination with TB-500 [2]. A 2026 Sports Medicine review that covers both constituents concludes that such unapproved peptides show promise in animals but that rigorous human safety data are scarce [1]. Both constituents are WADA-prohibited. This page reports research findings only and lists no human dose. ## What it is Wolverine is not a single chemical entity. It is a co-formulated research pairing of two structurally and mechanistically distinct synthetic peptides: 1. **BPC-157**: a fifteen-amino-acid (pentadecapeptide) sequence — Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val — derived from a cytoprotective protein in human gastric juice. Molecular weight approximately 1,419 Da. 2. **TB-500**: the N-terminally acetylated heptapeptide Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ), corresponding to residues 17-23 of the endogenous 43-residue protein thymosin beta-4. Molecular weight approximately 889 Da. The fragment sold as TB-500 is roughly five times smaller than the full parent protein whose literature it most often borrows. The blend has no single CAS number, molecular weight, or structure. Fixed-ratio vials (commonly labeled 10 mg + 10 mg) are distributed through research-supply channels without standardization or regulatory oversight [1]. ## How it works **BPC-157's mechanism** is best characterized as *angiogenic and cytoprotective*. A 2017 study spanning a chick chorioallantoic membrane model, rat hindlimb ischemia, and human vascular endothelial cells showed that BPC-157 increased the expression of VEGFR2 — the primary vessel-growth receptor — and promoted its internalization, activating the downstream VEGFR2-Akt-eNOS signaling pathway; blocking that internalization blocked the effect [4]. In practical terms: it makes blood-vessel cells more responsive to the body's own "grow new vessels" signal, and it accelerated blood-flow recovery in a blocked-circulation muscle model [4]. **TB-500's mechanism** operates at the other end of the repair process — inside migrating cells. Full-length thymosin beta-4 is the body's principal *G-actin sequestering* molecule: it forms a 1:1 complex with free, unpolymerized actin monomers and caps both ends, regulating the actin pool that cells draw on when they need to crawl toward a wound. A 2-angstrom X-ray crystal structure of a gelsolin-Tbeta4 hybrid confirmed the structural basis of this sequestration [6]. The cascading effects include faster cell migration, new vessel formation, reduced scar-forming myofibroblasts, and anti-inflammatory signaling [5]. The **combination rationale** is that these two arms — vascular supply (BPC-157) and cytoskeletal mobility (TB-500) — address non-overlapping bottlenecks in the same repair cascade. This is mechanistic reasoning from independently characterized evidence, not a finding from a study of the blend itself [2]. ## What the research shows *Regulatory and evidence framework.* A 2026 Sports Medicine narrative review naming both BPC-157 and TB-500 / thymosin beta-4 among unapproved musculoskeletal peptides concluded that animal-model promise is real but human safety data are scarce, potential for serious harm exists, and these compounds operate outside regulatory oversight [1]. *BPC-157 systematic review.* A 2025 HSS Journal systematic review of BPC-157 in orthopedic sports medicine analyzed 36 studies — 35 preclinical, only 1 human (a 12-patient retrospective intra-articular knee-pain report) — found "no clinical safety data" and classified the evidence as Level IV-V (lowest tiers). The review makes no mention of TB-500 or any combination study [2]. *BPC-157 narrative review.* A 2025 narrative review concluded that only three pilot studies have examined BPC-157 in humans, that rigorous large-scale trials are lacking, and that BPC-157 should be considered investigational and used with caution [3]. *BPC-157 angiogenesis (2017).* Across three models, BPC-157 upregulated VEGFR2 and activated the VEGFR2-Akt-eNOS pathway, with increased vessel density and accelerated blood-flow recovery; the effect was blocked by endocytosis inhibition [4]. *Thymosin beta-4 consolidated mechanism (2012).* A multi-model review established the full-length protein's actin-binding, pro-migratory, anti-scarring, anti-inflammatory and angiogenic activities as the rationale for clinical development [5]. *Actin-sequestration structure (2004).* X-ray crystallography at 2-angstrom resolution confirmed the 1:1 G-actin complex and dual-end capping mechanism of thymosin beta-4's LKKTETQ region — the structural basis for TB-500's entire cell-migration half of the blend [6]. *BPC-157 tendon (2003).* BPC-157 accelerated healing of fully transected rat Achilles tendons across biomechanical, functional, microscopic and macroscopic measures, and stimulated tendocyte growth in culture [7]. ## Reported effects, cautions & safety No community-use anecdote reports are compiled in this desk's source material specifically for the Wolverine two-peptide blend. The cautions below are drawn from the cited literature. - *No combination evidence.* The most important caution is structural: Wolverine has never been studied as a combination. All synergy claims are extrapolations from each peptide's independently characterized, largely non-overlapping mechanisms [2]. - *Overwhelmingly preclinical evidence.* BPC-157 has only three small human pilot studies; the TB-500 fragment has zero completed controlled human trials. The combination's human efficacy and safety are entirely unproven [2][3]. - *Fragment vs. full-protein identity gap.* Commercial TB-500 is the Ac-LKKTETQ heptapeptide (~889 Da), but most efficacy data attributed to it were generated with full-length thymosin beta-4 (~4,963 Da). The blend's TB-500 arm inherits this gap [5]. - *Theoretical tumor/angiogenesis signal.* Thymosin beta-4 is overexpressed in several cancers and implicated in metastasis and tumor angiogenesis; combining two pro-angiogenic peptides compounds this theoretical concern [5]. - *Non-regulated supply.* Product identity, purity and BPC-157:TB-500 ratio are unverified outside formal studies. Community loading-and-maintenance protocols have no controlled-trial basis. - *Banned in sport.* Both constituents are prohibited by WADA at all times: BPC-157 under S0 (non-approved substances), TB-500 / thymosin beta-4 under prohibited peptide/growth-factor categories [1]. - *Single-lab concentration.* A large share of the foundational BPC-157 literature originates from one research group (Sikiric and colleagues), which newer reviews flag as an independent-replication concern [3]. ![Wolverine BPC-157 TB-500 blend tissue-repair filament network in cold cyan graphite](/images/wolverine.webp) ## Where it fits Wolverine is the most prominent pairing in repair-blend research communities — and also the clearest illustration of this field's central challenge: a theoretically coherent combination rationale built from two peptides whose individual evidence is itself overwhelmingly preclinical, combined without any controlled study of the pairing. Read alongside [KLOW](/klow), which adds GHK-Cu and KPV to the same two-peptide core, and [GLOW](/glow), which pairs Wolverine's BPC-157 and TB-500 with GHK-Cu in a skin-and-repair framing. See the [comparison page](/compare) for the side-by-side. --- A literature digest of research-peptide blend constituents — citations and cautions, never a dose and never a product.